论文部分内容阅读
目的探讨P16蛋白表达在甲状腺癌发生、发展中的作用及其临床意义。方法采用免疫组织化学 SP法。结果 P16蛋白在PTC、FTC组织的表达率明显高于MTC和UDC组织的表达率(P<0.05)。Ⅰ期P16 蛋白的表达率明显高于Ⅲ、Ⅳ期(P<0.05)。无淋巴结转移组P16蛋白的表达率(92.6%)高于有淋巴结转移组 (64.7%)(P<0.05)。高分化组P16蛋白的表达率(90.3%)高于低分化组(61.5%)(P<0.05)。结论 P16蛋白参与了甲状腺癌的发生及分化,与甲状腺癌的临床分期、分化程度、淋巴结转移有关,可作为临床判定预后的参考指标之一。
Objective To investigate the role of P16 protein in the occurrence and development of thyroid carcinoma and its clinical significance. Methods Immunohistochemical SP method. Results The positive rate of P16 protein in PTC and FTC tissues was significantly higher than that in MTC and UDC tissues (P <0.05). The expression of stage P16 protein was significantly higher than that of stage Ⅲ and Ⅳ (P <0.05). The positive rate of P16 protein in non-lymph node metastasis group (92.6%) was higher than that in lymph node metastasis group (64.7%) (P <0.05). The positive rate of P16 protein in well-differentiated group (90.3%) was higher than that in poorly differentiated group (61.5%) (P <0.05). Conclusions P16 protein is involved in the occurrence and differentiation of thyroid carcinoma, which is related to the clinical stage, differentiation degree and lymph node metastasis of thyroid carcinoma. It may be used as one of the reference indexes for clinical judgment of prognosis.